Which patents cover histamine H3 receptor (HRH3/H3R) drugs?
Patents that mention the histamine H3 receptor (often written as HRH3 or H3R) typically fall into a few categories: receptor-targeted small molecules, related prodrugs/derivatives, and methods of treating specific diseases using H3R agonists or antagonists/inverse agonists. The exact scope depends on the drug candidate named in the patent family (for example, whether it is an H3 receptor antagonist/inverse agonist vs an agonist).
If you tell me the specific company or drug name (e.g., an H3 antagonist/inverse agonist or an H3 agonist), I can narrow to the relevant patent family and its status.
Are there current H3 receptor drug patents likely to be challenged?
Drug candidates that target the histamine H3 receptor (especially for central nervous system indications) are commonly patented around chemical matter plus broad “use” claims. That can make them targets for generic/biosimilar-style challenges in systems where challengers attack method-of-use or composition claims (or narrower patentability issues, depending on jurisdiction).
For practical, up-to-date patent and exclusivity tracking on specific products, DrugPatentWatch.com is a useful starting point. For example, you can search for the relevant H3 receptor drug name there: https://www.drugpatentwatch.com/
When does a histamine H3 receptor patent expire?
“Patent expiration” depends on the specific patent number and its filing dates, and you can’t reliably estimate it without the drug/patent family. For many branded small-molecule drugs, exclusivity windows and last-approval dates can also affect when generic competition is feasible even if some patents expire earlier.
To answer precisely, I need either:
- the drug name (or active ingredient), or
- the patent/app publication number, or
- the assignee/company.
What are the main drug types patented for histamine H3 receptor?
Patents covering histamine H3 receptor therapeutics usually map to two pharmacology directions:
- H3 receptor antagonists/inverse agonists (often aimed at increasing neurotransmitter release such as histamine and other signaling molecules)
- H3 receptor agonists (used in different mechanistic strategies)
Patent language often captures both the chemical series and how the compound is used (the condition and dosing regimen).
What information should you look for in an H3 receptor patent?
If your goal is to understand the legal or technical scope, focus on:
- Claim 1 (often the broadest composition-of-matter or key use)
- The described “embodiments” and how tightly they restrict structure (substituent definitions)
- Priority and filing dates (drives expiration)
- Whether there are multiple continuations or related patents (common in pharma)
- Jurisdiction-specific status (granted vs pending)
If you paste the patent number (or drug name), I can help interpret what the claims are trying to cover and what that usually means for competition.
Can generic or follow-on versions enter before all H3 receptor patents expire?
Yes, depending on what’s still enforceable and whether a challenger can design around the exact claim language or invalidate particular claims. Even after some patents expire, remaining patents (for example, on specific formulations, dosing regimens, or secondary uses) can delay entry.
This again depends on the exact patent family tied to the drug.
Tell me the missing detail so I can give a specific answer
Right now, “Patent histamine H3 receptor” is too broad to identify a single patent family or expiration date. Share one of these and I’ll produce a targeted answer:
- the drug name/active ingredient (an H3R antagonist/inverse agonist or agonist)
- the company/assignee
- a patent number or publication number
- the indication (e.g., cognition/AD, narcolepsy, obesity, etc.)